Bicyclic heterocycles as FGFR inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10947230
SERIAL NO

16566509

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • INCYTE CORPORATION; INCYTE HOLDINGS CORPORATION

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Qian, Ding-Quan Newark, US 87 2484
Sun, Yaping Lansdale, US 31 804
Wu, Liangxing Wilmington, US 162 5431
Xu, Meizhong Hockessin, US 66 2017
Yao, Wenqing Chadds Ford, US 324 9447
Zhang, Fenglei Berwyn, US 59 1996

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 16, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 16, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00